Contineum Therapeutics, Inc. Class A Common Stock (CTNM) earnings · last reported Oct 29, 2026
Next report
Around Thu, Mar 4, 2027
In 120 days · quarter ending Dec 2026
Not announced yet. Lician projection, not a company or provider date: the same quarter’s report a year ago plus 52 weeks.
Follow CTNM into its report
Save it to a free watchlist (no card). Alerts when the date moves or results land are part of Pro.
Earnings move
- Options price in
- — No upcoming report date.
- Average move after earnings
- ±2.0% Absolute close-to-close move, 3 reports
Options-implied move: the at-the-money straddle (call + put) on the first expiry after the report, divided by the stock’s close, from EODHD end-of-day option chains. It is what the options market prices as the absolute move to that expiry, not a forecast of direction. Move: close before the news → close after it (before the open: prior close → report-day close; after the close: report-day close → next close), adjusted for splits and dividends, from EODHD end-of-day prices. Reports with an unannounced time are not averaged: both candidate moves are stored instead. Per-report moves, gaps, moves vs SPY and the sector, beat/miss asymmetry and implied vs actual are in Lician Pro below.
Latest result
EPSGAAP
−$0.49
vs −$0.45 est. −8.9%
GAAP diluted EPS, SEC 10-Q
Provider (EODHD) showed −$0.45
Revenue
—
No revenue consensus stored
EPS actuals are checked against the SEC filing and the company’s earnings press release (8-K EX-99.1). A company that reports only GAAP EPS is graded on its SEC diluted EPS; one that reports adjusted EPS is graded on the provider’s adjusted figure when the release confirms it. A figure that matches neither is shown as unverified, with no beat or miss. Revenue actuals come from the SEC filing of the same quarter where we have it.
Beat / miss history
- Beat EPS in 3 of 4
- Oct 29, 2026MissEPS −$0.49GAAP vs −$0.45 −8.9%Rev — vs —
- Jul 30, 2026BeatEPS −$0.40GAAP vs −$0.46 +13.0%Rev — vs —
- May 5, 2026BeatEPS −$0.39GAAP vs −$0.53 +26.4%Rev — vs —
- Mar 5, 2026BeatEPS −$0.49GAAP vs −$0.65 +24.6%Rev — vs —
| Reported | Quarter | EPS est. | EPS actual | Surprise | Revenue est. | Revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | Sep 2026 | −$0.45 | −$0.49GAAP | −8.9% | — | — | — |
| Jul 30, 2026 | Jun 2026 | −$0.46 | −$0.40GAAP | +13.0% | — | — | — |
| May 5, 2026 | Mar 2026 | −$0.53 | −$0.39GAAP | +26.4% | — | — | — |
| Mar 5, 2026 | Dec 2025 | −$0.65 | −$0.49GAAP | +24.6% | — | — | — |
Earnings documents
- Earnings press releaseEX-99.1 · 8-K filed Nov 3, 2026Open on SEC.gov
Read the filing on LicianEDGAR filing index
Documents link to SEC EDGAR. Lician does not publish earnings-call transcripts.
Healthcare peers with similar quant ratings
CTNM is rated 2.76 of 5 among 532 rated Healthcare stocks (Lician quant rating, Nov 4, 2026). How the rating works
- ALT earnings2.79 · Hold · stock
- NAGE earnings2.79 · Hold · stock
- DMAC earnings2.77 · Hold · stock
- IPSC earnings2.77 · Hold · stock
- PRCT earnings2.76 · Hold · stock
- DSGN earnings2.75 · Hold · stock
- ANRO earnings2.74 · Hold · stock
- ACOG earnings2.73 · Hold · stock
| Quarter | Revenue | EPS | YoY |
|---|---|---|---|
| Q2 FY26 | — | −$0.40 | — |
| Q1 FY26 | — | −$0.39 | — |
| Q3 FY25 | — | −$0.45 | — |
| Q2 FY25 | — | −$0.62 | — |
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a biotechnology company listed on US.
Latest reported CTNM revenue for 2024-12-31 was $0. Net income was -$42.3M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. CTNM currently screens at market cap $429.6M.
When the next CTNM 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
The change that matters: Revenue was down 100.0% from 2023-12-31 to 2024-12-31. An earnings headline that ignores that move is noise.
Not investment advice. Full CTNM research stays on the stock page; the tape stays on the quote page.
CTNM earnings FAQ
When is CTNM's next earnings date?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has not announced it yet. Lician estimates the next report around Mar 4, 2027, based on the date it reported the same quarter a year ago. This is an estimate, not a confirmed date; the page updates when the provider lists one.
Did CTNM beat earnings estimates last quarter?
No. On Oct 29, 2026 Contineum Therapeutics, Inc. Class A Common Stock (CTNM) reported adjusted EPS of −$0.49 against a −$0.45 consensus (−8.9%), a miss.
How often does CTNM beat EPS estimates?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) beat the EPS consensus in 5 of its last 10 reported quarters.
What is CTNM's latest net income?
Latest cached Contineum Therapeutics, Inc. Class A Common Stock (CTNM) net income was -$42.3M. Statements: https://lician.com/financials/ctnm
What is CTNM's latest diluted EPS?
Latest cached Contineum Therapeutics, Inc. Class A Common Stock (CTNM) diluted EPS for Dec 31, 2024 was -$2.18.
What period does the latest CTNM earnings print cover?
The latest cached Contineum Therapeutics, Inc. Class A Common Stock (CTNM) earnings print covers Dec 31, 2024. The prior cached period on this page is Dec 31, 2023.
Where are CTNM earnings listed?
Cached earnings facts for Contineum Therapeutics, Inc. Class A Common Stock (CTNM) are listed at https://lician.com/earnings/ctnm. Statements: https://lician.com/financials/ctnm
Not investment advice.